drugset

drugset / Trial / NCT00233675

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

NCT00233675 ↗

Phase 3 Completed Cephalon

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Timeline

Start: 2003-08
Primary completion: 2005-02
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tiagabine	Small molecule	16 mg	—

Indications